



BIOLIGHT
Life Sciences Ltd.

Corporate Presentation



October 2024

* This is a translated version of Company's corporate presentation in Hebrew as filed with the Israeli TASE on October 14, 2024 – created for convenience purposes only.

Forward looking information

- This presentation was prepared by BioLight Life Sciences Ltd. ("BioLight") and contains summary information only. It does not include a detailed and/or complete description of BioLight, its subsidiaries, and holdings (collectively, the "Company"), its activities or forecasts regarding its activities, does not pretend to encompass or contain all the information required and/or that may be relevant for the purpose of making a decision regarding any investment in BioLight's securities is not intended to replace the requirement to examine all of the company's reports and/or any publication regarding the company that is currently published and/or will be published in the future. In order to get a complete picture of the activity and the risks, one should review the full reports submitted and/or to be submitted from time to time to the Securities Authority and the Tel Aviv Stock Exchange Ltd. BioLight does not provide any express or implied commitment or guarantee regarding the realization of the forecasts or the accuracy or completeness of the information included in this presentation and expressly disclaims all liabilities that may be based on such information, errors included in it, or omissions from it. It does not undertake to update, correct, or change the information included in this presentation in a way that will reflect updates, corrections, or editing of any future forecasts and/or future statements in order to reflect events or circumstances after the date of presentation of this presentation.
- The presentation includes forward-looking information as defined in the Securities Law, 5578 - 1968, which is largely based on BioLight's current and subjective expectations and assessments, forecasts, estimates, and other information relating to future events and matters, the degree to which they will materialize, all or in part, is uncertain and beyond BioLight's control. Additional facts and data that served as a basis for information are based on facts and data regarding the current state of BioLight, the company, and its businesses, facts, and data regarding the current state of the field of activity in which BioLight operates in its areas of activity, and macroeconomic facts and data, and all as known to BioLight at the time this presentation was prepared, including statistical and public data and publications published by various bodies and authorities, the content of which has not been checked by BioLight independently and therefore BioLight is not responsible for their correctness. The forward-looking information contained in the presentation may not materialize, in whole or in part, or may materialize differently than anticipated, or may be affected by factors that cannot be estimated in advance, and which are not under BioLight's control, due to a change in some of the risk factors that characterize the activities of BioLight and the company, as well as from developments in the economic environment and external factors affecting the company.
- This presentation does not constitute an offer, invitation, or solicitation to purchase BioLight securities and does not constitute a recommendation or opinion, or a substitute for an investor's judgment.



The **only entity in Israel** that invests solely in the growing space of ophthalmic diseases

97 Million ₪

Investment in Portfolio Companies

14 Million ₪

Current assets

7 Portfolio companies

2 Exits



Highly experienced Management team and scientific advisory committee

As of June 30, 2024

Holding Chart*



Subsidiaries - Build to Partner

 56% Strategic collaborations	 88%	 76% CSE listing in process
--	----------------	--

Affiliate

 36%

Exits & royalties' transaction

 SOLD! x2	 92% Sold for future royalties	 4% SOLD! 2.5-10x
------------------------	---	--

VC approach - Held companies

 5% Phase III	 5% Strategic investor	 8% FDA APPROVED X2 FDA APPROVED
----------------------------	-------------------------------------	---

Highly Experienced Management Team



Israel Makov

Chairman of the Board



Yaacov Michlin

CEO



Yiftach Biel

CFO



Karin Gurevitz

Vice President,
Legal Counsel



Scientific Advisory Board



Dr. Ron Neumann

BioLight's Chief Medical Officer (CMO), A leading expert ophthalmologist, specializing in inflammatory eye disease



Prof. Anat Loewenstein

Chairwoman of the Department of Ophthalmology at Ichilov Sourasky Medical Center & Vice Dean of Faculty, at the Sackler of Medicine at the Tel Aviv University



Dr. Joseph Tauber

World-renowned authority in the field of ocular surface diseases specifically in dry eye



Dr. Jeffrey Goldberg

Professor and Chair of Ophthalmology at the Byers Eye Institute at Stanford University, USA



Dr. Vicente Anido Jr.


Served as the CEO of Aerie Pharmaceuticals, an Ophthalmic Pharmaceutical company traded on the NASDAQ




Prevalence of eye diseases worldwide

 **340M** Suffer from Dry eye syndrome

 **146M** Suffer from Diabetic retinopathy

 **76M** Suffer from Glaucoma

 **190M** Suffer from Age-related Macular degeneration (AMD)

And this is only a small sample from a variety of eye diseases that affect billions of individuals worldwide

Today's Challenges

- Aging population
- Prevalence of eye disease rising
- Insufficient eye doctors in relation to population growth
- Fear of losing eyesight (blindness)

75%

of global vision impairment
can be avoided

Tomorrow's Solutions


- Early detection
- Better and personalized drugs
- Improved devices for procedure and implants
- Usage of digital health for remote diagnosis and accurate treatment

Eye market growth forecast

Average annual growth forecast for the eye market in the U.S. (drugs and medical device)

U.S. Ophthalmic Drugs Market
size. by drug class, 2020 - 2030 (USD Billion)


6.5% U.S. Market CAGR.
2022 -2030



Ophthalmology Markets

U.S Ophthalmic Devices market
size. by application. 2020 - 2030 (USD Billion)

4.4% U.S. Market CAGR.
2022 -2030




DiagnosTear

The Product

TeaRx™ technology is designed for the diagnosis of front-of-the-eye diseases by analyzing the composition of the tear fluid:

- DiagnosTear product designed for diagnosing dry eye (CE approved and Israeli MOH approved)
- DiagnosTear product designed for diagnosing Conjunctivitis (in clinical development phase)



DiagnosTear

The Challenge

- An ophthalmologist or a primary care doctor must have effective, accurate tools for diagnosing front-of-the-eye diseases

The Solution

- Identification of Dry Eye Syndrome and assessment of its underlying causes, personalized treatment and monitoring therapeutic outcomes.
- Clinical assessment of Red Eye; Differential diagnosis of ocular infections attributed to Herpes viruses, Adenoviruses and Allergic conjunctivitis

The Market

- Approximately 340 million patients suffer from dry eye syndrome worldwide
- Approximately 2% of visits to a primary care doctor are due to red eye



Expected next year

Share exchange, fund raising and listing on the Canadian Stock Exchange - funding mainly the Red Eye Product




Did you know?

Currently there is no fast-differentiating test for red eye in the doctor office



The Product

The insertion of a biodegradable sub-conjunctival implant for the slow and controlled release of a prescribed medication in a sustained manner for the treatment of glaucoma, inserted in the doctor's clinic once every few months (in an early clinical phase)





The Challenge

A significant part of patients suffering from glaucoma are not complying with the medication treatment on a timely manner, causing an increase in intraocular pressure and the progression of the disease which can lead to vision loss

The Solution

A biodegradable sub-conjunctival implant for the slow and controlled release of a known prescribed medication in a sustained manner for the treatment of glaucoma

The Market

Approximately 3 million people in the United States alone suffer from glaucoma

Approximately 50% of patients do not adhere to the treatment regimen as prescribed



Expected next year

- Fund raising
- Start human clinical trials



Did you know?

The market leading product (Durysta) is approved for one-time use compared to multi-use of Visci product



The Products

- A platform designed to deliver drugs to the retina aiming to reduce the need for injections
- Eye drops containing high dosage of Cyclosporine finished a successful Phase I human clinical trial phase





The Challenge

Increasing the penetrability and improving the tolerance of drug delivery to both the front and back of the eye

The Solution

OphRx technology, based on nanostructures and liquid molecules enhances the delivery of substances via a nanometric carrier system with the aim of facilitating the transmission of higher concentrations of ocular substances improving their conduction within the front of the eye and the retina

The Market

There is an enormous market for injectable drugs to treat retinal diseases. Reducing the need for injections and transitioning to the administration of eye drops is groundbreaking and has huge potential



Expected next year

Signed option to license with a global pharmaceutical company



Did you know?


The market of injection medication to the retina is estimated at \$18B (as of 2024)



The Product

Using innovative technology to identify biomarkers within the tear fluid specific to a particular retinal disease (or in the early stage of the disease) to facilitate the development of quick and non-invasive tests for early diagnosis of these diseases allowing the provision of personalized treatment which can prevent the progression of the disease

Retinal Pathology vs. Healthy controls





The Challenge

Considering the retina's crucial role in light absorption, converting it into nerve signals, and the initial processing of the visual input, any disease that impairs the function of the retina can lead to significant damage and even vision loss. Early diagnosis and prediction of the disease's progression are critical for providing preventative and personalized treatment approaches

The Solution

The discovery of novel biomarkers within tears that will enable the development of new tests for the diagnosis and classification of retinal diseases, such as Age-Related Macular Degeneration (AMD) which can be conducted directly inside a doctor's office

The Market

In 2022, the retinal market is estimated \$14B.

There is no early tear diagnosis for AMD and there is a huge market.



Expected next year

POC completion
Option for collaboration
with Alexion*



Did you know?


The AMD prevalence goes
from 12% at the age 60 to
27% at the age of 80

*An AstraZeneca subsidiary



The Product

Developing solutions for diagnosing and monitoring the regression of peripheral vision using a personal computer and its build-in camera using eye-tracking





The Challenge

Monitoring the regression of peripheral vision to improve treatment of Glaucoma Patients

The Solution

Peripherex technology, based on invention of the head of Ophthalmology in Stanford and Israeli eye tracking technology provides an objective 3 minutes per eye test of the peripheral vision. Peripherex home/clinic software product with the required level of accuracy compared to the current expensive market golden standard.

The Market

- Glaucoma is #1 cause for irreversible blindness.
- Over 50% of patients do NOT know they have Glaucoma.
- 100% of the Glaucoma patients do not know that they are getting worse at home.



Expected next year







Raise Funding and launch in the USA



Did you know?

Monitoring market for Glaucoma patients is estimated at \$1B

Held Companies

			Company Summary	Product Image	Potential
AEYE	8%		Develops artificial intelligence (AI) solutions for a variety of retinal diseases		Received two FDA approvals for its AI product that was developed in combination with a desktop and handled camera for autonomous detection of moderate to severe diabetic retinopathy, Addressing a market of approximately 460 million diabetic patients worldwide
Tarsier	5%		Develops an innovative product, the TRS01, for the treatment of inflammatory ocular diseases that may lead to blindness		Completed its first phase III clinical trial which examines the efficacy and safety of the TRS01 product for patients with non-infectious anterior uveitis, and those with uveitis-glaucoma. agreement with the FDA on the second stage phase III clinical trial primary and key secondary Endpoints.
Sanoculis	5%		Develops an innovative surgical procedure for the treatment for Glaucoma		Sanoculis signed a distribution agreement in Europe with B&L for 5 years and B&L has an option to purchase all Sanoculis assets till end of October 2024. Sanoculis advances clinical trials for FDA approvals.



Summary of significant expected events next year

DiagnosTear



- Share exchange, fund raising and listing on the Canadian Stock Exchange
- Developing the Red Eye Product



- Fund raising
- Start human clinical trials



Signed option to licenses with a global pharmaceutical company



- POC completion
- Option for collaboration with Alexion



Raise funding and launch in the USA



Continuing sales in Europe by B&L

Investments compared to potential value*

	Invested in KNIS	Market potential indicator
DiagnosTear	25,616	Estimated market value of \$14.8 million, subject to successful listing on the CSE (approximately NIS 56 million)
Visci	36,570	As per actual investment amount
LipiCare	4,100	Depending on future royalty proceeds paid by Chemipal (if and when paid)
Ophrx	4,618	As per actual investment amount
Peripherex	5,147	As per actual investment amount

*As of June 30, 2024

Investments compared to potential value*


	Invested in KNIS	Market potential indicator
Belkin	3,839	Actual proceeds received of approximately NIS 9 million and conditional future proceeds of approximately up to \$10.8 million (c. NIS 40 million) in the coming years based on Alcon sales milestones achievements (in the financial statements c. NIS 8,874 thousands)
Sanoculis	5,915	In the financial statements c. NIS 6,488 thousands
AEYE	6,537	~ 2 years ago, fund raising was with approximately \$55 million valuation, reflecting company's holding value of approximately \$4 million (c. NIS 15 million, in the financial statements c. NIS 6,210 thousands)
Tarsier	4,638	Last fund raising was with approximately \$100 million valuation, reflecting company's holding value of approximately \$4.2 million (c. NIS 16 million, non-significant amount in the financial statements)

Total	96,980
--------------	---------------

The tables above are based on a NON-GAAP presentation regarding consolidated and/or portfolio companies (together - Portfolio Companies) which present indicators for potential future value according to transactions on the agenda (the realization of which is uncertain) and based on the Company's current holding rate in the Portfolio Companies, in which an external investment round was conducted (if it occurred) or a merger transaction was completed (Belkin) or a listing for trading may take place (DiagnosTear) or there is an option for a third party to acquire the activity (Sanoculis). It should be emphasized that the investment value in the Portfolio Companies is as detailed in the company's reports. The indicators for potential future value based on transactions as mentioned above constitute forward-looking statement as defined in the Israeli Securities Law, 1968, which there is no certainty regarding its realization and may not materialize or may materialize differently (even materially) than expected. The Company believes that the tables below, along with the explanation beside them, may help to understand the Company's asset situation and constitute supporting information alongside the detailed information regarding these assets provided in the Company's reports and its periodic and immediate reports, including the Company's financial statements prepared according to accepted accounting principles. It should be emphasized that the information included in the tables above does not substitute for the information included in the Company's reports, as published on the reporting site ('Magna') of the Israel Securities Authority and the Tel Aviv Stock Exchange.

* As of June 30, 2024

Main Shareholders *



*As of September 30, 2024,
as reported to the company



BIOLIGHT
Life Sciences Ltd.

THANK YOU

E-mail: BioLight@bio-light.co.il

Website: <http://bio-light.co.il>